VERTEX PHARMACEUTICALS INC / MA Revenue Breakdown
No Revenue Breakdown for VRTX on this site yet.
- 2025-12-31: Others Not split by product in the filing$12.00B100.00%; Total revenue $12.00B.
- 2024-12-31: Others Not split by product in the filing$11.02B100.00%; Total revenue $11.02B.
- 2023-12-31: Others Not split by product in the filing$9.87B100.00%; Total revenue $9.87B.
- 2022-12-31: Others Not split by product in the filing$8.93B100.00%; Total revenue $8.93B.
Source checked: the stored Revenue Breakdown page for VRTX.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $12.00B 100.00% | $12.00B |
| 2024-12-31 | Not split by product in the filing $11.02B 100.00% | $11.02B |
| 2023-12-31 | Not split by product in the filing $9.87B 100.00% | $9.87B |
| 2022-12-31 | Not split by product in the filing $8.93B 100.00% | $8.93B |
| 2021-12-31 | Not split by product in the filing $7.57B 100.00% | $7.57B |
| 2020-12-31 | Not split by product in the filing $6.21B 100.00% | $6.21B |
| 2019-12-31 | Not split by product in the filing $4.16B 100.00% | $4.16B |
| 2018-12-31 | Not split by product in the filing $3.05B 100.00% | $3.05B |
| 2017-12-31 | Not split by product in the filing $2.49B 100.00% | $2.49B |
| 2016-12-31 | Not split by product in the filing $1.70B 100.00% | $1.70B |
| 2015-12-31 | Not split by product in the filing $1.03B 100.00% | $1.03B |
| 2014-12-31 | Not split by product in the filing $580.41M 100.00% | $580.41M |
| 2013-12-31 | Not split by product in the filing $1.21B 100.00% | $1.21B |
| 2012-12-31 | Not split by product in the filing $1.53B 100.00% | $1.53B |
| 2011-12-31 | Not split by product in the filing $1.41B 100.00% | $1.41B |
| 2010-12-31 | Not split by product in the filing $143.37M 100.00% | $143.37M |
| 2009-12-31 | Not split by product in the filing $101.89M 100.00% | $101.89M |
| 2008-12-31 | Not split by product in the filing $175.50M 100.00% | $175.50M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $3.33B 100.00% | $3.33B |
| 2026-03-31 | Not split by product $2.99B 100.00% | $2.99B |
| 2025-12-31 | Not split by product $3.19B 100.00% | $3.19B |
| 2025-09-30 | Not split by product $3.08B 100.00% | $3.08B |
| 2025-06-30 | Not split by product $2.96B 100.00% | $2.96B |
| 2025-03-31 | Not split by product $2.77B 100.00% | $2.77B |
| 2024-12-31 | Not split by product $2.91B 100.00% | $2.91B |
| 2024-09-30 | Not split by product $2.77B 100.00% | $2.77B |
| 2024-06-30 | Not split by product $2.65B 100.00% | $2.65B |
| 2024-03-31 | Not split by product $2.69B 100.00% | $2.69B |
| 2023-12-31 | Not split by product $2.52B 100.00% | $2.52B |
| 2023-09-30 | Not split by product $2.48B 100.00% | $2.48B |
| 2023-06-30 | Not split by product $2.49B 100.00% | $2.49B |
| 2023-03-31 | Not split by product $2.37B 100.00% | $2.37B |
| 2022-12-31 | Not split by product $2.30B 100.00% | $2.30B |
| 2022-09-30 | Not split by product $2.33B 100.00% | $2.33B |
| 2022-06-30 | Not split by product $2.20B 100.00% | $2.20B |
| 2022-03-31 | Not split by product $2.10B 100.00% | $2.10B |
| 2021-12-31 | Not split by product $2.07B 100.00% | $2.07B |
| 2021-09-30 | Not split by product $1.98B 100.00% | $1.98B |
| 2021-06-30 | Not split by product $1.79B 100.00% | $1.79B |
| 2021-03-31 | Not split by product $1.72B 100.00% | $1.72B |
| 2020-12-31 | Not split by product $1.63B 100.00% | $1.63B |
| 2020-09-30 | Not split by product $1.54B 100.00% | $1.54B |
| 2020-06-30 | Not split by product $1.52B 100.00% | $1.52B |
| 2020-03-31 | Not split by product $1.52B 100.00% | $1.52B |
| 2019-12-31 | Not split by product $1.41B 100.00% | $1.41B |
| 2019-09-30 | Not split by product $949.83M 100.00% | $949.83M |
| 2019-06-30 | Not split by product $941.29M 100.00% | $941.29M |
| 2019-03-31 | Not split by product $858.43M 100.00% | $858.43M |
| 2018-12-31 | Not split by product $870.11M 100.00% | $870.11M |
| 2018-09-30 | Not split by product $784.53M 100.00% | $784.53M |
| 2018-06-30 | Not split by product $752.16M 100.00% | $752.16M |
| 2018-03-31 | Not split by product $640.80M 100.00% | $640.80M |
| 2017-12-31 | Not split by product $651.63M 100.00% | $651.63M |
| 2017-09-30 | Not split by product $578.16M 100.00% | $578.16M |
| 2017-06-30 | Not split by product $544.13M 100.00% | $544.13M |
| 2017-03-31 | Not split by product $714.72M 100.00% | $714.72M |
| 2016-12-31 | Not split by product $458.71M 100.00% | $458.71M |
| 2016-09-30 | Not split by product $413.78M 100.00% | $413.78M |
| 2016-06-30 | Not split by product $431.61M 100.00% | $431.61M |
| 2016-03-31 | Not split by product $398.08M 100.00% | $398.08M |
| 2015-12-31 | Not split by product $417.94M 100.00% | $417.94M |
| 2015-09-30 | Not split by product $309.82M 100.00% | $309.82M |
| 2015-06-30 | Not split by product $166.08M 100.00% | $166.08M |
| 2015-03-31 | Not split by product $138.51M 100.00% | $138.51M |
| 2014-12-31 | Not split by product $144.56M 100.00% | $144.56M |
| 2014-09-30 | Not split by product $178.99M 100.00% | $178.99M |
| 2014-06-30 | Not split by product $138.42M 100.00% | $138.42M |
| 2014-03-31 | Not split by product $118.45M 100.00% | $118.45M |
| 2013-12-31 | Not split by product $351.16M 100.00% | $351.16M |
| 2013-09-30 | Not split by product $221.70M 100.00% | $221.70M |
| 2013-06-30 | Not split by product $310.75M 100.00% | $310.75M |
| 2013-03-31 | Not split by product $328.37M 100.00% | $328.37M |
| 2012-12-31 | Not split by product $333.99M 100.00% | $333.99M |
| 2012-09-30 | Not split by product $336.01M 100.00% | $336.01M |
| 2012-06-30 | Not split by product $418.31M 100.00% | $418.31M |
| 2012-03-31 | Not split by product $438.74M 100.00% | $438.74M |
| 2011-12-31 | Not split by product $563.34M 100.00% | $563.34M |
| 2011-09-30 | Not split by product $659.20M 100.00% | $659.20M |
| 2011-06-30 | Not split by product $114.42M 100.00% | $114.42M |
| 2011-03-31 | Not split by product $73.66M 100.00% | $73.66M |
| 2010-12-31 | Not split by product $65.52M 100.00% | $65.52M |
| 2010-09-30 | Not split by product $23.80M 100.00% | $23.80M |
| 2010-06-30 | Not split by product $31.62M 100.00% | $31.62M |
| 2010-03-31 | Not split by product $22.43M 100.00% | $22.43M |
| 2009-12-31 | Not split by product $33.89M 100.00% | $33.89M |
| 2009-09-30 | Not split by product $24.96M 100.00% | $24.96M |
| 2009-06-30 | Not split by product $19.06M 100.00% | $19.06M |
| 2009-03-31 | Not split by product $23.98M 100.00% | $23.98M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |